Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 51 entries
View as:

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00475917 Org: User:
Start: 05/31/07 End: 12/31/08 Due: 12/31/09

Study of XL281 in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00451880 Org: User:
Start: 02/28/07 End: 10/31/11 Due: 10/31/12

A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06952010 Org: User:
Start: 05/01/25 End: 11/30/27 Due: 11/30/28

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00596648 Org: User:
Start: 12/31/07 End: - Due: -

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01865747 Org: User:
Start: 06/30/13 End: 01/15/21 Due: 01/15/22

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01100619 Org: User:
Start: 04/30/10 End: - Due: -

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05425940 Org: User:
Start: 09/07/22 End: 02/28/26 Due: 02/28/27

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00350831 Org: User:
Start: 07/31/06 End: - Due: -

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05678673 Org: User:
Start: 01/01/23 End: 06/30/28 Due: 06/30/29

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05176483 Org: User:
Start: 12/14/21 End: 06/28/30 Due: 06/28/31

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05932862 Org: User:
Start: 04/03/24 End: 08/03/29 Due: 08/03/30

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05144347 Org: User:
Start: 04/12/22 End: 11/01/22 Due: 11/01/23

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01493869 Org: User:
Start: 09/30/11 End: 08/31/14 Due: 08/31/15

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Phase: N/A Priority: Normal
NCT ID: NCT04446117 Org: User:
Start: 06/30/20 End: 10/16/26 Due: 10/16/27

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03755791 Org: User:
Start: 06/10/18 End: 12/01/24 Due: 12/01/25

Study of XL820 in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00129571 Org: User:
Start: 08/31/05 End: - Due: -

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Phase: N/A Priority: Normal
NCT ID: NCT00570635 Org: User:
Start: 12/31/07 End: 05/31/09 Due: 05/31/10

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01995058 Org: User:
Start: 12/31/13 End: 11/30/14 Due: 11/30/15

Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00960492 Org: User:
Start: 09/30/09 End: 10/31/13 Due: 10/31/14

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Phase: N/A Priority: Normal
NCT ID: NCT06191796 Org: User:
Start: 01/25/24 End: 05/12/25 Due: 05/12/26

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01896479 Org: User:
Start: 12/31/14 End: 12/31/23 Due: 12/31/24

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00704730 Org: User:
Start: 06/30/08 End: 09/30/20 Due: 09/30/21

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00464113 Org: User:
Start: 05/31/07 End: 04/30/11 Due: 04/30/12

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03937219 Org: User:
Start: 06/25/19 End: 06/30/26 Due: 06/30/27

Study of XL418 in Adults With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00460278 Org: User:
Start: 04/30/07 End: - Due: -